HR-Positive Breast Cancer: Integration of Genomic Testing and Multidisciplinary Decision-Making

This segment explores the growing role of genomic testing and multidisciplinary coordination in the management of hormone receptor–positive, HER2-negative metastatic breast cancer. Dr. Adam Brufsky brings attention to how institutions are incorporating next-generation sequencing into clinical workflows and whether testing is standardized across practices.

Ms. Lori Brisbin describes a system-level approach in which genomic testing is strongly encouraged for patients with metastatic disease, often supported by collaboration between diagnostics teams and pharmacy. She highlights that advances in circulating tumor DNA testing have improved turnaround times, making molecular profiling more accessible in real-world practice.

The discussion also underscores variability in assay platforms and interpretation, as well as the absence of standardized thresholds for biomarkers such as ESR1 mutation burden. Importantly, Ms. Brisbin notes that patients are increasingly engaged in decision-making based on genomic results. Overall, this segment highlights the evolving integration of molecular testing into treatment planning and its impact on clinical decision-making.